PIOGLITAZONE HYDROCHLORIDE
PIOZONE 30MG TABLET
30mg Tablet
Indication*
Treatment of type 2 diabetes mellitus as monotherapy in patients whose hyperglycemia cannot be controlled by diet and exercise alone, to decrease insulin-resistance and blood glucose levels, In combination with a sulfonylurea, metformin or insulin when adequate glycemic control is not achieved by diet, exercise and monotherapy.
Directions for Use*
Include nutritional counseling, weight reduction (as needed), and exercise in the management of type 2 diabetes. Individualize antidiabetic therapy based on glycemic control and patient's response to treatment. Patients should be carefully monitored for adverse reactions related to fluid retention and signs of congestive heart failure after initiation of pioglitazone or with dose increase. Liver enzymes should be carefully monitored for adverse reactions related to fluid retention and signs of congestive hear failure after initiation of pioglitazone or with dose increase. liver enzymes should be checked prior to initiation of pioglitazone therapy, As adverse eg, edema and weight gain appear to be dose-related, the smallest effective dose should be used. During treatment initiation and dose titration, fasting plasma glucose should be used to determine the therapeutic response to pioglitazone HCI and identify the minimum effective dose. Thereafter, glycosylated hemoglobin (HbA1c) should be measured at intervals of approximately 3 months. Monotherapy: Patients without Congestive Heart Failure: Starting Dose: 15 mg or 30 mg once daily, with or without meals. Patients with NYHA Class I or II Heart Failure: Starting Dose: 15 mg once daily. Dosage may be titrated in increments of 15 mg up to a maximum of 45 mg once daily based on glycemic response as determined by HbAc1. Combination Therapy with Sulfonylurea: Pioglitazone in combination with a sulfonylurea may be initiated at 15 mg or 30 mg once daily. Continue current sulfonylurea dose when starting pioglitazone therapy. Decrease the sulfonylurea dose if patients report hypoglycemia during combination therapy. Combination with Insulin: Continue current insulin dose upon starting pioglitazone therapy. Decrease insulin dose by 10-25% if the patient reports hypoglycemia or if fasting plasma glucose (FPG) decrease to <100 mg/dL. Individualize further adjustment based on the glucose-lowering response. Co-administration with Strong CYP2C8 Inhibitors: Maximum Recommended Dose: 15 mg once a day. Missed Dose: When a dose is missed, pioglitazone should be taken as soon as the patient remembers. In cases where the time is too close to the next dose, the missed dose should be skipped and treatment should be resumed with the next scheduled dose.
Administration*
May be taken with or without food.
*written indications, directions, and administration are updated as of February 13, 2024 and may not be accurate with the actual product purchased. Please read the details in the packaging.
|
Your Price
Regular price ₱37.00 |
Member Price
Regular price |
Couldn't load pickup availability
